Squalene(Synonyms: 角鲨烯; Super Squalene; trans-Squalene; AddaVax)

上海金畔生物科技有限公司提供天然产物萜类及其苷类Terpenoids and Glycosides。

Squalene (Synonyms: 角鲨烯; Super Squalene; trans-Squalene; AddaVax) 纯度: ≥98.0%

Squalene 是胆固醇合成的中间产物,具有多种药理活性,例如降血脂、保肝、保护心脏、抗氧化及抗毒性等。Squalene 还具有抗真菌活性,可用于毛癣菌治疗的相关研究。

Squalene(Synonyms: 角鲨烯; Super Squalene;  trans-Squalene;  AddaVax)

Squalene Chemical Structure

CAS No. : 111-02-4

规格 价格 是否有货 数量
Free Sample (0.1-0.5 mg)   Apply now  
10 mM * 1 mL in DMSO ¥550 In-stock
5 mg ¥500 In-stock
10 mg   询价  
50 mg   询价  

* Please select Quantity before adding items.

Squalene 相关产品

相关化合物库:

  • Natural Product Library Plus
  • Drug Repurposing Compound Library Plus
  • FDA-Approved Drug Library Plus
  • FDA-Approved Drug Library Mini
  • Bioactive Compound Library Plus
  • Anti-Infection Compound Library
  • Immunology/Inflammation Compound Library
  • Metabolism/Protease Compound Library
  • NF-κB Signaling Compound Library
  • Stem Cell Signaling Compound Library
  • Natural Product Library
  • FDA-Approved Drug Library
  • Human Endogenous Metabolite Compound Library
  • Anti-Aging Compound Library
  • Drug Repurposing Compound Library
  • Antioxidants Compound Library
  • Lipid Compound Library
  • Oxygen Sensing Compound Library
  • Anti-Cardiovascular Disease Compound Library
  • Antifungal Compound Library
  • Ferroptosis Compound Library
  • NMPA-Approved Drug Library
  • Terpenoids Library
  • Pyroptosis Compound Library
  • Orally Active Compound Library
  • Traditional Chinese Medicine Monomer Library
  • FDA Approved & Pharmacopeial Drug Library
  • Microbial Metabolite Library
  • Mitochondria-Targeted Compound Library
  • Food-Sourced Compound Library

生物活性

Squalene is an intermediate product in the synthesis of cholesterol, and shows several pharmacological properties such as hypolipidemic, hepatoprotective, cardioprotective, antioxidant, and antitoxicant activity. Squalene also has anti-fungal activity and can be used for the research of Trichophyton mentagrophytes treatment[2].

IC50 & Target

Human Endogenous Metabolite

 

Clinical Trial

分子量

410.72

Formula

C30H50

CAS 号

111-02-4

中文名称

鲨烯;角鲨烯

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Pure form -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : 16.67 mg/mL (40.59 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.4347 mL 12.1737 mL 24.3475 mL
5 mM 0.4869 mL 2.4347 mL 4.8695 mL
10 mM 0.2435 mL 1.2174 mL 2.4347 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 1.67 mg/mL (4.07 mM); Clear solution

    此方案可获得 ≥ 1.67 mg/mL (4.07 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 16.7 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH₂O 中,得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: 1.67 mg/mL (4.07 mM); Suspended solution; Need ultrasonic

    此方案可获得 1.67 mg/mL (4.07 mM) 的均匀悬浊液,悬浊液可用于口服和腹腔注射。

    以 1 mL 工作液为例,取 100 μL 16.7 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中,再用生理盐水定容至 10 mL,完全溶解,澄清透明
  • 3.

    请依序添加每种溶剂: 10% DMSO    90% corn oil

    Solubility: ≥ 1.67 mg/mL (4.07 mM); Clear solution

    此方案可获得 ≥ 1.67 mg/mL (4.07 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 16.7 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

*以上所有助溶剂都可在 Shanghai Jinpan Biotech Co Ltd 网站选购。
参考文献
  • [1]. Muzalevskaya EN, et al. SQUALENE: PHYSIOLOGICAL AND PHARMACOLOGICAL PROPERTIES. Eksp Klin Farmakol. 2015;78(6):30-6.

    [2]. E Gnamusch, et al. Effect of squalene on the structure and function of fungal membranes. Journal of Dermatological Treatment. Volume 3, 1992 – Issue sup1